证券代码:000411 证券简称:英特集团 浙江英特集团股份有限公司投资者关系活动记录表 编号:2023-007 □特定对象调研 □分析师会议 投资者关系 □媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 ■其他 2023 年半年度业绩机构交流会 参与单位名称 中信证券、德邦证券、信达证券、兴业证券、东北证券、永赢基金、申万资管、泰康资产、光 大证券、国诚投资、山海皆可平资管等机构投资者 时间 2023年9月1日下午14:00—15:00 地点 公司会议室 董事兼副总经理费荣富、董事会秘书谭江、运营副总监许可、财务负责人曹德智、战略规划与 上市公司接待 人员姓名 证券事务部(董事会办公室) 总经理刘金喜、证券事务代表裘莉 一、公司半年度业绩情况介绍 二、投资者提问与回答 (一)2023年半年度公司利润增长的原因是什么? 回答:2023年半年度,公司实现归属于上市公司股东的净利润2.78亿元,同比增长142.27%。 利润增长的主要原因,一是今年公司完成以发行股份及支付现金的方式购买省国贸集团和华辰 投资合计持有英特药业50%股权,并向康恩贝募集配套资金事项。英特药业50%股权已于2月2 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥16,002,063,040.83, representing a 9.23% increase compared to ¥14,650,227,368.93 in the same period last year[24]. - Net profit attributable to shareholders was ¥278,011,103.63, a significant increase of 142.27% from ¥114,753,204.30 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was ¥204,697,066.03, up 88.83% from ¥108,405,352.68 in the previous year[24]. - Basic earnings per share increased to ¥0.64, a rise of 72.97% compared to ¥0.37 in the same period last year[24]. - Total assets at the end of the reporting period reached ¥15,155,714,279.59, marking a 15.13% increase from ¥13,163,827,738.71 at the end of the previous year[24]. - Net assets attributable to shareholders increased by 85.79% to ¥3,871,397,766.49 from ¥2,083,702,746.60 at the end of the previous year[24]. - The company reported a net cash flow from operating activities of -¥178,514,731.49, an improvement from -¥289,491,511.54 in the previous year[24]. - The company's total revenue for the reporting period reached ¥16,002,063,040.83, representing a year-on-year increase of 9.23% compared to ¥14,650,227,368.93 in the same period last year[65]. - The gross profit margin for pharmaceutical sales decreased by 0.48% to 5.76%, with sales amounting to ¥15,105,643,428.81, up 11.03% year-on-year[68]. - Research and development expenses decreased by 9.71% to ¥4,048,663.62 from ¥4,484,272.03 in the previous year[65]. - The net cash generated from financing activities increased significantly by 149.35% to ¥2,027,749,188.23, compared to ¥813,203,344.03 in the previous year[66]. - The net cash and cash equivalents increased by 273.49% to ¥1,771,602,570.62, up from ¥474,333,908.06 in the same period last year[65]. - The company's total assets as of June 30, 2023, amounted to 13,513,009,490.44 CNY, an increase from 11,656,574,393.64 CNY at the beginning of the year[184]. - The company's net profit after deducting non-recurring gains and losses for the first half of 2023 was 26,913.57 million CNY, representing a 12.45% increase compared to the same period last year[181]. - The company's asset-liability ratio increased to 71.20% from 70.50% year-on-year, reflecting a 0.70% increase[181]. - The interest coverage ratio improved significantly to 6.00, up 32.45% from 4.53 in the previous year[181]. Strategic Initiatives - The company aims to enhance its market position through strategic initiatives and potential acquisitions[4]. - The company completed a major asset restructuring, acquiring 50% equity of Yingtai Pharmaceutical, enhancing asset quality and profitability[43]. - The company successfully acquired 51% of Baishan Medical, marking an expansion into the medical device sector[44]. - The company is expanding its non-bid market sales through the "Yingte Pharmacy Valley" B2B e-commerce platform, enhancing its market reach[40]. - The company has established a market expansion department that has built strong relationships with top domestic and international suppliers, facilitating new product market entry[57]. - The company is focusing on innovative business models, including the establishment of a new international company to enter the cross-border e-commerce sector in the pharmaceutical health industry[62]. - The company is committed to high-quality growth through lean management practices aimed at cost reduction and efficiency improvement[61]. - The company is focused on enhancing its market share while exploring new models and business formats in the pharmaceutical distribution sector[97]. Compliance and Governance - The report emphasizes the importance of accurate financial reporting and the responsibility of the board and management[4]. - The financial report includes a commitment to transparency and adherence to regulatory requirements[4]. - The management discussed potential risks and related measures in the future development section of the report[4]. - The company has not faced any administrative penalties for environmental issues during the reporting period[113]. - The company is actively participating in the "Beautiful Zhejiang" initiative, focusing on energy conservation and emission reduction measures[113]. - The company emphasizes the importance of compliance and quality management in the pharmaceutical industry to mitigate risks related to product quality and safety[98]. - The company has maintained a good integrity status, with no significant debts or court judgments unfulfilled during the reporting period[124]. Shareholder and Capital Structure - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase capital from reserves[5]. - The company raised RMB 400 million through the issuance of 48,899,755 shares at a price of RMB 8.18 per share, netting RMB 395.47 million after fees[88]. - The total number of common shareholders at the end of the reporting period was 25,894[160]. - Zhejiang International Trade Group Co., Ltd. holds 29.84% of shares, totaling 150,846,400 shares, with an increase of 76,463,120 shares during the reporting period[161]. - Zhejiang Huachen Investment Development Co., Ltd. holds 24.19% of shares, totaling 122,277,100 shares, with an increase of 70,581,340 shares during the reporting period[161]. - The company’s stock issuance and fundraising activities are aimed at enhancing its capital structure and supporting future growth initiatives[158]. - The company’s shareholders include Zhejiang International Trade Group and Huachen Investment, which hold significant stakes post-issuance[158]. Operational Efficiency - The company has implemented a multi-level lean management team to enhance operational efficiency and service quality through digital information platforms and lean tools[61]. - The company has established six modern logistics centers in Zhejiang Province, covering a logistics warehouse area of 250,000 square meters and a cold storage volume of 30,000 cubic meters, with an annual throughput of over 20 million items[56]. - The logistics platform improved order fulfillment efficiency, with enhanced cold chain capabilities and a new integrated scheduling platform[50]. - The company has adopted a customer-centric approach with grid management to improve service quality and operational efficiency[54]. - The company has implemented measures to manage accounts receivable effectively, addressing the challenges posed by the growing scale of operations[100]. Product Development and Innovation - Over 50 new imported patented and domestic innovative products were introduced in the first half of the year, strengthening product offerings[45]. - The company has introduced over 50 new imported and domestic innovative products in the first half of the year, enhancing its product resource construction in the breast cancer segment[59]. - The company operates over 190 offline stores and has more than 300 product specifications for DTP business, actively exploring online cooperation models with various hospitals[60]. Legal and Regulatory Matters - The company reported a total of 8 litigation cases during the reporting period, with a total amount involved of 2.914 million yuan, and 5 cases have been concluded[123]. - The company has not experienced any major litigation or arbitration matters during the reporting period[122]. - The company has not reported any bankruptcy reorganization matters during the reporting period[123]. - The semi-annual financial report has not been audited[120].

| 证券代码:000411 | | --- | | 债券代码:127028 | 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 2023 年 8 月 15 日，浙江英特集团股份有限公司以电子邮件、专人送达方式向全体监事 发出了召开九届十七次监事会议的通知，会议于 2023 年 8 月 25 日以通讯表决方式召开，会 议应到监事 5 人，出席会议的监事 5 人，缺席会议的监事 0 人。本次会议的召开符合有关法 律、行政法规、部门规章、规范性文件和公司章程的规定。会议采用记名表决方式对通知中 所列事项进行了表决，形成以下决议： 一、审议通过了《2023 年半年度报告及摘要》（同意 5 票、反对 0 票、弃权 0 票）。 经审核，监事会认为董事会编制和审议浙江英特集团股份有限公司 2023 年半年度报告 的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 相关内容披露在同日的巨潮资讯网（http://www.cninfo.com.cn）和证券时报上。 二、审议通过了《关于部分 ...

中信证券股份有限公司 关于浙江英特集团股份有限公司 部分募投项目延期之核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）作为浙江英 特集团股份有限公司（以下简称"英特集团"或"公司"）2020 年公开发行可转 换公司债券及持续督导的保荐机构，根据《中华人民共和国公司法》《中华人民 共和国证券法》《证券发行上市保荐业务管理办法》等有关规定，对公司募投项 目延期事项进行了审慎核查，并发表如下核查意见： 一、募集资金及募投项目基本情况 经中国证券监督管理委员会《关于核准浙江英特集团股份有限公司公开发行 可转换公司债券的批复》（证监许可[2020]3159 号）核准，同意公司向社会公开 发行面值总额 60,000 万元可转换公司债券，期限 6 年。本次发行募集资金共计 60,000 万元，上述募集资金到位情况经天职国际会计师事务所（特殊普通合伙） 验证，并由其出具《验证报告》（天职业字[2021]465 号）。 | 序号 | 项目名称 | 项目投资总额 | 募集资金投入额 | | --- | --- | --- | --- | | | | （万元） | （万元） | | 1 | 英特药谷运营中心 | ...

| | 浙江英特药业有限责任公司 | 子公司 | | 其他应收款 | 94,850.00 | 48,409.78 | 1,999.85 | 74,499.85 | 70,759.78 | 资金 | 非经营性 往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | 拆借 | | | 上市公司的子公司及其附属企业 | 浙江英特物联网有限公司 | 子公司 | | 其他应收款 | 7,402.03 | 5,568.63 | 14.97 | 5,162.69 | 7,822.94 | 资金 | 非经营性 | | | | | | | | | | | | 拆借 | 往来 | | | 浙江英特药谷电子商务有限公司 | 子公司 | | 其他应收款 | 5,517.37 | | | | 5,517.37 | 资金 | 非经营性 | | | | | | | | | | | | 拆借 | 往来 | | 其他关联方及其附属企业 | 华润医药商业集团有限公司及其子 华润医药商业集团有限公司及其 ...

| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2023-071 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 关于子公司申请办理应收账款无追索权保理业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、保理业务概况 为降低应收账款余额，加速资金周转，保障经营资金需求，公司全资子公司浙江英特药 业有限责任公司（简称"英特药业"）拟向中国民生银行股份有限公司（杭州分行）申请办 理应收账款无追索权保理业务。 2023 年 8 月 25 日，公司九届三十二次董事会议审议通过了《关于子公司申请办理应收 账款无追索权保理业务的议案》（11 票同意，0 票反对，0 票弃权）。本项业务经公司董事会 批准后即可实施，无需公司股东大会或政府有关部门批准。 本次保理业务不构成关联交易，不构成《上市公司重大资产重组管理办法》规定的重大 资产重组。 二、交易对方的基本情况 公司在产权、业务、资产、债权债务、人员等方面不存在可能或已经造成对交易对方利 益倾斜的关系。 通过"信 ...

浙江英特集团股份有限公司独立董事 1、报告期内，公司不存在控股股东及其他关联方违规占用公司资金的情况。 2、截至本报告期末，公司对外担保余额为50,506.09万元，占报告期末净资产的比例为 13.05%。 3、公司已制定《对外担保管理制度》，规定了对外担保的审批权限、程序、信息披露 及责任追究，建立了完善的对外担保风险控制制度。上述担保已按照法律法规、《公司章 程》及《对外担保管理制度》的规定履行了必要的审议程序。同时，公司按规定及时履行 了信息披露义务，充分揭示了对外担保存在的风险。截至本报告日，没有明显迹象表明公 司可能因被担保方债务违约而承担担保责任。 综上所述，公司对外担保符合中国证监会、银监会《关于规范上市公司对外担保行为的 通知》和《公司章程》的规定。 二、关于子公司申请办理应收账款无追索权保理业务的独立意见 为降低应收账款余额，加速资金周转，保障经营资金需求，公司全资子公司浙江英特药 业有限责任公司申请办理应收账款无追索权保理业务，有利于企业的业务发展，符合公司和 全体股东的利益，我们同意浙江英特药业有限责任公司办理应收账款无追索权保理业务。 关于公司九届三十二次董事会议相关事项的独立意见 三 ...

| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2023-070 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 根据中国证监会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》、深圳证券交易所《上市公司自律监管指引第 1 号——主板上市公司规 范运作》及相关格式指引的规定，浙江英特集团股份有限公司（以下简称"英特集团"或"公司"） 将 2023 年半年度募集资金存放与使用情况报告如下： 一、募集资金基本情况 （一）公开发行可转换公司债券 1、实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于核准浙江英特集团股份有限公司公开发行可转换公司 债券的批复》（证监许可[2020]3159 号）核准，同意公司向社会公开发行面值总额 60,000 万 元可转换公司债券，期限 6 年。本次发行募集资金共计 60,000 万 ...

| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2023-067 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 三、审议通过了《关于部分募投项目延期的议案》（11 票同意，0 票反对，0 票弃权）。 相关内容披露在同日的巨潮资讯网（http://www.cninfo.com.cn）和证券时报上。 九届三十二次董事会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 2023 年 8 月 15 日，浙江英特集团股份有限公司以电子邮件、专人送达方式向全体董 事发出了召开九届三十二次董事会议的通知，会议于 2023 年 8 月 25 日以通讯表决方式召 开。会议应到董事 11 人，实际出席会议的董事 11 人，缺席会议的董事 0 人。本次会议的 召开符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。会议采用记名 表决方式对通知中所列事项进行了表决，形成以下决议： 一、审议通过了《2023 年半年度报告及摘要》（11 票同意，0 票反对，0 票弃权 ...

| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2023-072 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 关于部分募投项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江英特集团股份有限公司（以下简称"英特集团"、"公司"）于 2023 年 8 月25日召开 九届三十二次董事会议和九届十七次监事会议，审议通过了《关于部分募投项目延期的议案》， 同意公司在对募集资金投资项目实施主体、实施地点不发生改变的前提下，对部分募集资金投 资项目进行延期。现将具体情况公告如下： 一、募集资金及募投项目基本情况 经中国证券监督管理委员会《关于核准浙江英特集团股份有限公司公开发行可转换公司债 券的批复》（证监许可[2020]3159 号）核准，同意公司向社会公开发行面值总额 60,000 万元可 转换公司债券，期限 6 年。本次发行募集资金共计 60,000 万元，本次募集资金总额扣除保荐承 销费用 5,188,679.25 元（不含税）后的实收募集资金为 ...